Research for Life

CANQURA AB (Sweden) is dedicated to the treatment of cancer using its novel and patented ISCOM G2 and G3 Nanoparticulate Technology. We have proven success data in early stage tests for AML, Prostate and Renal cancers.

Canqura AB and Q-Vant Biosciences, Inc have now joined forces and to collaborate on in a JV to take this discovery from pre-clinical phase to a successful clinical phase I/IIa.

WE ARE NOW ACTIVELY seeking investment partners and Investors to build on our current successes in research to the next level.
See more under Company Strategy